A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

checkorphan
Learn more about:
Fuchs endothelial corneal dystrophy
Related Clinical Trial
The BELGIAN ENDOTHELIAL SURGICAL TRANSPLANT of the CORNEA Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) Descemet Endothelial Thickness Comparison Trial II Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty TTHX1114(NM141) in Combination With DWEK/DSO A Phase 1/ Phase 2 Study of TTHX1114(NM141) Predictive Factors of Good Results After Primary Descemet’s Membrane Endothelial Keratoplasty (DMEK) Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch’s Endothelial Corneal Dystrophy A Comparison of Visual Functions and Side-effects After DSAEK or DMEK for Fuchs’ Endothelial Dystrophy DSAEK- Postoperative Positioning and Transplant Dislocation Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) PIONEER: Intraoperative and Perioperative OCT Study DISCOVER Study: Microscope-integrated Intraoperative OCT Study Study of Endothelial Keratoplasty Outcomes Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty Using the Optovue OCT to Select IOL Power The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK DMEK Versus DSAEK Study Technique And Results In Endothelial Keratoplasty Air Versus SF6 for Descemet’s Membrane Endothelial Keratoplasty (DMEK) Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation Comparing Endoglide to Endoserter for DSAEK Graft Insertion Comparison of Corneal Grafts Cultured in Serum-free Versus Corneal Grafts Cultured in Serum Supplemented Culture Media Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea Fuchs’ Torsional Phaco Study Risk Assessment for Progression to DMEK Following Cataract Surgery in Fuchs Endothelial Corneal Dystrophy Comparison of Two Techniques in Achieving Corneal Graft OCT-guided DSAEK Graft Shaping and Smoothing Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections. Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy Rhopressa for Corneal Edema Associated With Fuchs Dystrophy ODM 5 in the Treatment of Corneal Edematous Fuchs’ Endothelial Dystrophy Assessment of Corneal Endothelial Function Following Hypoxic Stress Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration Analysis of the Genotype/Phenotype Relationship in the Fuchs’ Corneal Endothelial Dystrophy in France. Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis Fuchs’ Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs’ Dystrophy Glanatec(R) for Descemet Stripping in Fuch’s Endothelial Dystrophy Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs’ Endothelial Dystrophy Study of the Effect of Aspheric Lenses in Patients With Fuch’s Dystrophy Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT The Molecular Pathogenesis of Late-onset Fuchs’ Endothelial Corneal Dystrophy

Brief Title

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

Official Title

A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study

Brief Summary

      This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension
      (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with
      Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of
      up to 15 days and an 18-month Double-Masked Treatment Period.

Study Phase

Phase 2

Study Type

Interventional

Primary Outcome

Change from baseline in best corrected visual acuity (BCVA) with contrast level of 100% at Month 18

Secondary Outcome

 Best corrected visual acuity (BCVA) with contrast level of 100% at all post-baseline visits

Condition

Fuchs Endothelial Corneal Dystrophy

Intervention

STN1010904 ophthalmic suspension 0.03% BID

Study Arms / Comparison Groups

 STN1010904 ophthalmic suspension 0.03% BID
Description:

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

80

Start Date

May 19, 2022

Completion Date

March 2025

Primary Completion Date

March 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Male or female diagnosed with FECD.

        Exclusion Criteria:

          -  Females who are pregnant or lactating.

          -  Any ocular surgery for FECD (e.g., penetrating keratoplasty (PKP), Descemet stripping
             endothelial keratoplasty (DSEK), Descemet membrane endothelial keratoplasty (DMEK),
             Descemet stripping automated endothelial keratoplasty (DSAEK), Descemet stripping only
             (DSO) in the study eye.

Gender

All

Ages

30 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

, +1 415-268-9100, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT05376176

Organization ID

101090401IN

Responsible Party

Sponsor

Study Sponsor

Santen Inc.

Collaborators

 ActualEyes Inc.

Study Sponsor

, ,

Verification Date

June 2022